Trinity Biotech (NASDAQ:TRIB) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a research report released on Wednesday morning. The firm issued a buy rating on the stock.

Trinity Biotech Stock Performance

NASDAQ TRIB opened at $1.85 on Wednesday. The stock has a 50-day simple moving average of $2.04 and a two-hundred day simple moving average of $2.25. The firm has a market capitalization of $14.10 million, a P/E ratio of -0.58 and a beta of 1.21. Trinity Biotech has a fifty-two week low of $1.79 and a fifty-two week high of $5.50.

Trinity Biotech (NASDAQ:TRIB) last released its quarterly earnings data on Wednesday, January 31st. The company reported ($0.90) earnings per share for the quarter. The business had revenue of $14.68 million during the quarter. As a group, analysts forecast that Trinity Biotech will post -1.5 earnings per share for the current year.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.